Exact Sciences (EXAS) Tops Q4 EPS by 27c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Nasdaq ends lower as oil prices surge ahead of earnings, economic data
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Exact Sciences (EXAS) PT Lowered to $65 at BTIG
February 20, 2025 6:47 AM ESTBTIG analyst Mark Massaro lowered the price target on Exact Sciences (NASDAQ: EXAS) to $65.00 (from $75.00) while maintaining a Buy rating.
The analyst comments "Consistent with the company's pre-announce last month, EXAS delivered a modest Q4 revenue beat, as screening and precision oncology in 2024 grew +13% and +4% Y/Y, respectively. In... More



